Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBIT Margin: 2016-2024

Historic EBIT Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to -31.51%.

  • Akebia Therapeutics' EBIT Margin rose 4098.00% to 7.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.88%, marking a year-over-year decrease of 22809.00%. This contributed to the annual value of -31.51% for FY2024, which is 43105.00% up from last year.
  • Latest data reveals that Akebia Therapeutics reported EBIT Margin of -31.51% as of FY2024, which was up 93.19% from -462.56% recorded in FY2023.
  • Over the past 5 years, Akebia Therapeutics' EBIT Margin peaked at -27.62% during FY2022, and registered a low of -462.56% during FY2023.
  • For the 3-year period, Akebia Therapeutics' EBIT Margin averaged around -173.90%, with its median value being -31.51% (2024).
  • As far as peak fluctuations go, Akebia Therapeutics' EBIT Margin soared by 273,465bps in 2020, and later slumped by 43,494bps in 2023.
  • Over the past 5 years, Akebia Therapeutics' EBIT Margin (Yearly) stood at -128.23% in 2020, then skyrocketed by 326bps to -124.97% in 2021, then spiked by 9,735bps to -27.62% in 2022, then plummeted by 43,494bps to -462.56% in 2023, then skyrocketed by 43,105bps to -31.51% in 2024.